CTLA4 and neoplasm: Anti-CTLA-4-induced blockade of regulatory T-cell function may contribute to the recruitment of novel adaptive immune specificities, as evidenced by the frequent development of autoimmune complications on combination immunotherapy [2], and some of these T-cell clones may eliminate tumor indirectly, such as by targeting the microenvironment [27].